Michael Amoroso - Mar 21, 2025 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
President and CEO, Director
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso
Stock symbol
DTIL
Transactions as of
Mar 21, 2025
Transactions value $
-$5,360
Form type
4
Date filed
3/25/2025, 06:00 PM
Previous filing
Feb 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +3.42K +3.19% 111K Mar 21, 2025 Direct F1, F2
transaction DTIL Common Stock Sale -$5.36K -964 -0.87% $5.56 110K Mar 24, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -3.42K -100% $0.00 0 Mar 21, 2025 Common Stock 3.42K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the vesting of Restricted Stock Units ("RSUs") on March 21, 2025.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 On March 21, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. The RSUs vested in full on March 21, 2025.